Nano-ETM is a nanoemulsion drug delivery system developed by LATITUDE Pharmaceuticals for highly insoluble drugs. It can be used for small molecule, peptide, and protein drugs across various routes of administration including intravenous, intramuscular, subcutaneous, and oral. The technology is the formulation behind two drugs currently in NDA review and is a versatile platform that can load up to 5% of drug by weight while maintaining bioequivalence to solution formulations. It offers significant advantages like neutral pH, non-irritation, and compatibility with IV administration.

1. Nano-E™
Nanoemulsion Drug Delivery System for Highly Insoluble Drugs
LATITUDE Pharmaceuticals, Inc.’s Nanoemulsion Drug Delivery System (Nano-E™) is a
versatile drug delivery platform for applications requiring a liquid formulation for highly insoluble small
molecule, peptide, and protein drugs. Nano-E is being used in several NDA-stage and clinical-stage
products.
The Nano-E™ technology is the 505(b)(2)-enabling formulation behind two NDA-stage compounds
that LATITUDE developed for its clients.
LATITUDE Pharmaceuticals, Inc. | 9675 Businesspark Ave, San Diego, CA 92131 | Tel: 858-546-0924 | Fax: 858-546-0958 | www.latitudepharma.com
Key Advantages and Properties of Nano-E™ Technology
 Highly versatile drug delivery platform for insoluble or soluble
compounds
 Small molecule and protein friendly
 pH neutral, non irritating, non-allergenic: clinically proven
significant safety improvement for vein-irritating drugs
 For IV, IM, SC, IP, intrathecal, intra-articular, ophthalmic, oral
routes of delivery
 IV bolus and infusion enabling
 Up to 5% drug loading by weight
 Tissue friendly and wound compatible
 Dilutable in standard IV diluents (e.g., D5W)
 All components are GRAS listed compendial grade (USP, NP,
EP)
 Does not contain co-solvents (e.g., Cremophor) or detergents
(e.g., polysorbate)
 PK profile bio-equivalent to solution formulations
 RT stability demonstrated for 1.5-2 years
 Filterable through 0.2 micron fiiters
 Lyophilizable as needed
 Simple and straightforward manufacturing
 Manufacturing feasibility demonstrated for two NDA-stage drugs
 Patent pending